Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$0.96
$0.010.82%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.20% | -1.91% | 3.61% | 9.63% | 5.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.20% | -1.91% | 3.61% | 9.63% | 5.26% |
| Cost of Revenue | -5.57% | -2.91% | -0.04% | 1.37% | -2.78% |
| Gross Profit | -6.57% | -1.33% | 5.82% | 14.87% | 10.50% |
| SG&A Expenses | -5.59% | -1.70% | 4.99% | 14.61% | 9.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -271.40% | -165.69% | -197.93% | -287.65% | 2,213.31% |
| Total Operating Expenses | -7.15% | -3.70% | 1.59% | 7.53% | 3.77% |
| Operating Income | -2.59% | 5.21% | 11.81% | 18.34% | 11.38% |
| Income Before Tax | -9.34% | 17.29% | 55.11% | 67.06% | 17.28% |
| Income Tax Expenses | -14.72% | 6.08% | 20.64% | 21.52% | 9.36% |
| Earnings from Continuing Operations | -6.76% | 22.97% | 74.26% | 93.93% | 21.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.10% | 28.63% | 83.92% | 88.14% | 16.89% |
| EBIT | -2.59% | 5.21% | 11.81% | 18.34% | 11.38% |
| EBITDA | -0.11% | 7.58% | 13.20% | 20.59% | 11.64% |
| EPS Basic | -7.41% | 24.97% | 82.56% | 91.31% | 20.35% |
| Normalized Basic EPS | -13.99% | 13.28% | 52.82% | 68.25% | 21.48% |
| EPS Diluted | -7.41% | 24.97% | 82.56% | 91.31% | 20.35% |
| Normalized Diluted EPS | -13.99% | 13.28% | 52.82% | 68.25% | 21.48% |
| Average Basic Shares Outstanding | 4.81% | 3.45% | 1.54% | -0.69% | -3.18% |
| Average Diluted Shares Outstanding | 4.81% | 3.45% | 1.54% | -0.69% | -3.18% |
| Dividend Per Share | 163.91% | 44.93% | -12.94% | -5.87% | -56.19% |
| Payout Ratio | -0.08% | -0.51% | -0.50% | -0.32% | -0.09% |